Revium Rx Advances Toward Phase 1 Clinical Development of Nano-Mupirocin to Combat Antibiotic-Resistant Infections

Core Insights - Revium Rx is advancing its lead product candidate, Nano-Mupirocin, aimed at treating severe bacterial infections by overcoming the limitations of traditional mupirocin formulations [1][2][3] Regulatory and Clinical Development - The company submitted a clinical trial application to the Israeli Ministry of Health, marking a significant step towards initiating first-in-human studies in early 2026 [3] - Revium Rx is collaborating with WuXi AppTec to scale up and produce its GMP clinical batch, with final release expected by the end of 2025 [3] Addressing Antimicrobial Resistance (AMR) - MRSA caused approximately 130,000 deaths in 2021, a significant increase from 57,200 in 1990, highlighting the urgent need for new systemic antibiotics [4][5] - The Global Research on Antimicrobial Resistance (GRAM) Project indicates that AMR was responsible for 1.27 million deaths globally in 2019, with projections suggesting that AMR-related fatalities could reach 2 million annually by 2050 without intervention [4] Market Opportunity - The global AMR therapeutics market was valued at USD 8.7 billion in 2023 and is projected to exceed USD 12.5 billion by 2030, growing at a CAGR of 5.3% [6] - Nano-Mupirocin targets high-value infectious disease indications, including MRSA, VRE, and Ceftriaxone-Resistant Gonorrhea, positioning the company to capture a meaningful share of the expanding market [7]